Abstract Details

Title Embolic Strokes of Undetermned Source in young adults: Incidence, Risk Factors and long-Term outcome

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 151

Objective We aim to compare the clinical characteristics in young adults with ESUS and other aetiological subgroups of strokes.

Background Embolic strokes of undetermined source (ESUS) are a new clinical entity, not yet throughly investigated in young stroke patients. In this population based-study, we aimed to compare the clinical characteristics, risk factors as well as outcomes in young adults with ESUS and other aetiological subgroups of strokes.

Design/Methods We included 70 patients aged between 18 and 45 years old with first-ever ischemic stroke (IS). Stroke etiologies were classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST), and ESUS patients were identified according to the criteria of Cryptogenic Stroke/ESUS International Working Group. Among these patients, we compared ESUS and other-subgroups population.

Results Among 70 patients, 19 (27%) were classified as ESUS. They were younger (median age was 35 years vs. 39 Years). Male sex was less common in ESUS (59,2% vs 63,6%). ESUS were of moderate severity (median National Institute Health Stroke Scale score was 5). They had fewer cardiovascular risk factors than other TOAST groups (less hypertension (24,6% vs. 32,7%, p<0,01), diabetes (16,9% vs. 32,7; p<0·01), hypercholesterolaemia (15,3% vs. 25,4%; p<0·01), and history of smoking (31,5 % vs. 43,2 %; p=0·01). About 89% of patients with ESUS were treated with antiplatelet therapy, while only 11% had received an anticoagulant therapy. A low risk of recurrence stroke was noted in ESUS population (4% vs 13,7%). Patients with ESUS had more favorable functional outcomes (median Modified Rankin Scale score: 0 vs 1).

Conclusions In our cohort, ESUS patients were younger and had milder cardiovascular risk factor burden and generally better long-term outcome compared to other causes of young ischemic stroke. Anti-platelet agents remain the first-line treatment for ESUS patients.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Ines Bedoui	No disclosure on file
	No disclosure on file
	No disclosure on file
Jamel Zaouali	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details